KALRAY
Kalray (Euronext Growth Paris : ALKAL) (Paris:ALKAL), a leading provider in the new generation of processors and acceleration cards specialized in Intelligent Data Processing from Cloud to Edge, is delighted to announce the first outcome of the synergetic combination of its DPU (“Data Processing Unit”) processor-based acceleration card K200-LP™ with newly acquired software-defined storage and data management solutions provider pixitmedia1 , a division of Arcapix Holdings Ltd dedicated to the Media & Entertainment markets. The launch of this new joint product comes just months after Kalray's acquisition of Arcapix Holdings Ltd and the new product will be showcased at Flash Memory Summit (USA) in August.
KALRAY’S ACCELERATION CARDS AND DPUs AT THE HEART OF AWARDED PIXITMEDIA’S SOFTWARE-DEFINED STORAGE AND DATA MANAGEMENT SOLUTIONS
Media & Entertainment customers are amongst the most demanding in terms of data storage and data management. The award winning pixstor and ngenea products are deployed by industry leading film studios, broadcasters, postproduction houses and VFX studios, all of whom derive value from the way in which pixitmedia puts the creative user in control of their data. Guaranteed performance, security compliance and flexibility in choice of deployment in a Hybrid, Multi-Cloud world are all a given, but it’s the smart integration with the customer’s workflow and creative pipeline management tools that elevates pixitmedia’s storage credentials.
Just a few months after Kalray’s acquisition of Arcapix Holdings Ltd, Kalray and pixitmedia have combined their technologies to offer a new version of pixstor and ngenea capable of leveraging the Kalray K200-LP™ Smart Storage Acceleration card. This combination of software and hardware offers new perspectives in terms of performance, power consumption, flexibility and, ease of use for pixitmedia’s customers in the Media & Entertainment industry.
KALRAY'S K200-LP™ DEVELOPED FOR HIGH PERFORMANCE STORAGE AND NEXT GENERATION OF DATA MANAGEMENT SOLUTIONS
K200-LP™ is the perfect solution for storage appliance makers and cloud service providers, to build their next generation of storage appliances in terms of performance per Watt per dollar.
Leveraging Kalray’s MPPA® DPU, a new generation of high performance processors tailored to process data-intensive applications, the K200-LP™ Smart Storage Accelerator cards can be programmed to accelerate rich and demanding data services.
Media & Entertainment applications require highly efficient storage and data management solutions while offering a unified, easy to use, collaborative environment for the content creators. In this context, the K200-LP™ card offers new opportunities to improve each step within the typical content workflow .
“With the K200-LP™ , we’re able to both consolidate and turbo-charge many of our existing storage-related functions and features that will help us offer even more efficient solutions to our customers. We look forward to exploiting the full power of our MPPA® DPU-based acceleration cards in the future within pixstor and ngenea, be it for accelerating our ability to help customers realize the full value of their existing content with machine learning in pixstor, or reducing the time it takes to shares assets globally with ngenea ”, said Barry Evans, Kalray Storage Business CTO and co-founder of Pixitmedia.
The K200-LP™ Smart Storage Accelerator card as well as Pixitmedia DPU-empowered solution will be showcased at Flash Memory Summit, booth #940, from August 2 to 4, 2022, at Santa Clara Convention Center, CA, USA.
ACCELERATING THE MARKET PENETRATION OF KALRAY’S ACCELERATION CARDS
One of the acquisition goals of Arcapix Holdings Ltd, of which pixitmedia is part, by Kalray was to increase growth opportunities, accelerate the commercialization of its technology and products, and leverage cross-selling opportunities. pixitmedia now gives access to new markets opportunities for Kalray, including one of the most demanding and exciting data-intensive industries – Media & Entertainment.
The integration of Kalray’s Cards into pixitmedia’s servers is an important milestone and will contribute to accelerate Kalray’s time-to-market on this specific market.
Eric Baissus, President and CEO of Kalray said: “The synergy with Arcapix is now a reality that customers can experience! We are proud to have a combined solution ready just a few months after the acquisition. It shows both the complementarity of our offering and the unique collaborative mindset that we managed to instill within our company .”
About KALRAY
Kalray (Euronext Growth Paris - FR0010722819 - ALKAL) is a fabless semiconductor company, a leading provider of a new class of processors, specialized in Intelligent Data Processing from Cloud to Edge. Kalray’s team have created and developed its leading edge technology and products to help its clients maximize the market possibilities presented by a world dominated by massive, disparate and pervasive data.
Thanks to Kalray’s patented manycore architecture, Kalray’s MPPA® Intelligent Data Processors are natively capable of managing multiple workloads with no bottlenecks to enable smarter, more efficient and energy-wise data-intensive applications. Kalray's offering includes processors, acceleration cards with associated software environment and appliances, allowing its customers to design the best solutions in fast growing sectors such as modern data centers, 5G, AI and Edge Computing, autonomous vehicles and others.
Founded in 2008 as a spin-off of CEA French lab, with investors such as Alliance Venture (Renault-Nissan-Mitsubishi), Safran, NXP Semiconductors, CEA and Bpifrance, Kalray is dedicated through technology, expertise and passion to offer more: More for a smart world, more for the planet, more for customers and developers. www.kalrayinc.com
1 pixitmedia is the dedicated division for Media & Entertainment markets of Arcapix Holdings Ltd, acquired by Kalray. See press release on March 3, 2022.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220627005583/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom